"Piperidines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of hexahydropyridines.
| Descriptor ID |
D010880
|
| MeSH Number(s) |
D03.383.621
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperidines".
Below are MeSH descriptors whose meaning is more specific than "Piperidines".
This graph shows the total number of publications written about "Piperidines" by people in this website by year, and whether "Piperidines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 2 | 2 | 4 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 1 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 4 | 3 | 7 |
| 2004 | 0 | 1 | 1 |
| 2005 | 3 | 1 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 3 | 2 | 5 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 3 | 4 |
| 2011 | 3 | 3 | 6 |
| 2012 | 2 | 3 | 5 |
| 2013 | 1 | 2 | 3 |
| 2014 | 2 | 3 | 5 |
| 2015 | 2 | 6 | 8 |
| 2016 | 2 | 3 | 5 |
| 2017 | 2 | 2 | 4 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 3 | 5 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperidines" by people in Profiles.
-
A Retrospective Review of Tofacitinib in the Treatment of Refractory Dermatomyositis. J Drugs Dermatol. 2022 Oct 01; 21(10):1133-1134.
-
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study. J Hematol Oncol. 2022 07 16; 15(1):96.
-
Tofacitinib Ameliorates Retinal Vascular Leakage in a Murine Model of Diabetic Retinopathy with Type 2 Diabetes. Int J Mol Sci. 2021 Nov 02; 22(21).
-
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies. Epilepsy Res. 2021 08; 174:106646.
-
Hypohidrotic Ectodermal Dysplasia with c.28delG Mutation in Ectodysplasin A Gene and Severe Atopic Dermatitis Treated Successfully with Tofacitinib. Acta Derm Venereol. 2021 Jan 04; 101(1):adv00352.
-
Tofacitinib in the treatment of lichen planopilaris: A retrospective review. J Am Acad Dermatol. 2020 Nov; 83(5):1487-1489.
-
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematol Oncol. 2020 Aug; 38(3):353-362.
-
Cross-Talk between Transforming Growth Factor-? and Periostin Can Be Targeted for Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2020 02; 62(2):204-216.
-
Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. Arthritis Care Res (Hoboken). 2019 10; 71(10):1387-1395.
-
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2391-2402.